OncoMatch/Clinical Trials/NCT07711847
Personalized Prone Immobilization for Accelerated Partial Breast Radiotherapy
Is NCT07711847 recruiting? Yes, currently enrolling (Sep 2026). This NA trial studies VENUS SHELL™ immobilization device for invasive breast cancer early stages.
Treatment: VENUS SHELL™ immobilization device — The goal of this clinical trial is to find out whether using a personalized breast holder (called VENUS SHELL™) can improve positioning and patient comfort during prone radiotherapy (radiotherapy given while the patient lies on her stomach). The main goals of the study are: * To confirm that using the VENUS SHELL™ is safe and effective * To assess whether the VENUS SHELL™ helps deliver accurate radiation treatment in a faster and more comfortable way Participants will: * Attend a study visit before radiotherapy to have a breast surface scan (no radiation) and enable the production of their personalized VENUS SHELL™ * Use their VENUS SHELL™ during radiotherapy planning and treatment * Be asked to complete questionnaires about their comfort
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Excluded: BRCA1 mutation
Known germline BRCA1/2 mutation
Excluded: BRCA2 mutation
Known germline BRCA1/2 mutation
Disease stage
Required: Stage PT1, PT2, PTIS (other)
Staging pT1-T2, N0M0 (Tumor size ≤3 cm); Staging pTis (tumor size ≤3 cm)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
ECOG/WHO performance status ≤2
Demographics
Prior therapy
Must have received: breast conservative surgery
Upfront breast conservative surgery
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NYU Grossman School of Medicine · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07711847 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received breast conservative surgery.
Are patients with BRCA1 alterations eligible?
No. BRCA1 mutation is an exclusion criterion.
Are patients with BRCA2 alterations eligible?
No. BRCA2 mutation is an exclusion criterion.
What disease stage is eligible?
Stage PT1 or PT2 or PTIS is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages